文献速递血脂与心血管预防

超越10年风险:他汀类药物用于心血管疾病一级预防的成本效果分析

Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.
PubMed 文献 · Circulation · 2022-03-07

该研究从苏格兰卫生部门视角,采用计算机模拟模型预测≥40岁苏格兰成年人长期健康与成本结局,评估扩大他汀预防性治疗资格及新的优先级策略的成本效果。主要结局为终生增量成本效果比(每获得一个质量调整生命年的成本,2020年英镑)。结果显示,将ASSIGN评分阈值从≥20%降至≥10%可扩大合格人群且具成本效果;基于绝对风险降低(ARR)指导的治疗比10年风险评分更有效且具成本效果;年龄分层风险阈值策略均被支配。

要点

  • 将ASSIGN评分阈值从≥20%降至≥10%扩大他汀合格人群且具成本效果。
  • ARR指导的治疗比10年风险评分更有效且具成本效果。
  • 年龄分层风险阈值策略被支配(更贵且更无效)。

核心结论

  • 仿制药定价使预防性他汀治疗对许多成年人具成本效果。
  • ARR指导的治疗比10年风险评分更有效且具成本效果。

研究设计与样本

  • 计算机模拟模型预测苏格兰≥40岁成年人长期健康与成本结局。
  • 流行病学分析使用苏格兰心脏健康扩展队列、苏格兰发病率记录和国家记录。
  • 模拟队列基于2011年苏格兰健康调查数据和当代人口估计构建。

主要发现

  • 两种年龄分层风险阈值策略均被支配(更贵且更无效)。

临床怎么用

  • 可考虑将他汀一级预防的ASSIGN评分阈值从≥20%降至≥10%以扩大治疗资格。
  • ARR指导的治疗策略比10年风险评分更有效且具成本效果,可作为优先级排序方法。
  • 年龄分层风险阈值策略不被支持,因其更贵且更无效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cholesterol guidelines typically prioritize primary prevention statin therapy on the basis of 10-year risk of cardiovascular disease. The advent of generic pricing may justify expansion of statin eligibility. Moreover, 10-year risk may not be the optimal approach for statin prioritization. We estimated the cost-effectiveness of expanding preventive statin eligibility and evaluated novel approaches to prioritization from a Scottish health sector perspective. METHODS: A computer simulation model predicted long-term health and cost outcomes in Scottish adults ≥40 years of age. Epidemiologic analysis was completed using the Scottish Heart Health Extended Cohort, Scottish Morbidity Records, and National Records of Scotland. A simulation cohort was constructed with data from the Scottish Health Survey 2011 and contemporary population estimates. Treatment and cost inputs were derived from published literature and health service cost data. The main outcome measure was the lifetime incremental cost-effectiveness ratio, evaluated as cost (2020 GBP) per quality-adjusted life-year (QALY) gained. Three approaches to statin prioritization were analyzed: 10-year risk scoring using the ASSIGN score, age-stratified risk thresholds to increase treatment rates in younger individuals, and absolute risk reduction (ARR)-guided therapy to increase treatment rates in individuals with elevated cholesterol levels. For each approach, 2 policies were considered: treating the same number of individuals as those with an ASSIGN score ≥20% (age-stratified risk threshold 20, ARR 20) and treating the same number of individuals as those with an ASSIGN score ≥10% (age-stratified risk threshold 10, ARR 10). RESULTS: Compared with an ASSIGN score ≥20%, reducing the risk threshold for statin initiation to 10% expanded eligibility from 804 000 (32% of adults ≥40 years of age without CVD) to 1 445 500 individuals (58%). This policy would be cost-effective (incremental cost-effectiveness ratio, £12 300/QALY [95% CI, £7690/QALY-£26 500/QALY]). Incremental to an ASSIGN score ≥20%, ARR 20 produced ≈8800 QALYs and was cost-effective (£7050/QALY [95% CI, £4560/QALY-£10 700/QALY]). Incremental to an ASSIGN score ≥10%, ARR 10 produced ≈7950 QALYs and was cost-effective (£11 700/QALY [95% CI, £9250/QALY-£16 900/QALY]). Both age-stratified risk threshold strategies were dominated (ie, more expensive and less effective than alternative treatment strategies). CONCLUSIONS: Generic pricing has rendered preventive statin therapy cost-effective for many adults. ARR-guided therapy is more effective than 10-year risk scoring and is cost-effective.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kohli-Lynch CN, Lewsey J, Boyd KA, et al. Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease. Circulation. 2022. PMID: 35249370. doi:10.1161/CIRCULATIONAHA.121.057631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。